NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Latigo Biotherapeutics, Inc. (LTGO) Stock Analysis

Latigo Biotherapeutics, Inc. (LTGO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

LTGO

$23.04

+$0.56 (+2.49%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LTGO with… →

LTGO Key Statistics

As of Sep 4, 2026
Trading
Open
$22.68
Previous Close
$22.48
Day's Range
22.02–23.57
52-Week Range
17.22–25.93
Volume
226.40K
Valuation
Market Cap
$1.53B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.89
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$109.17M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
66.30M
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
380.40K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

LTGO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$109.17M—
2024$0.00−$61.18M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$110.39M−$109.17M—
2024$0.00—−$63.45M−$61.18M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LTGO Valuation vs Biotechnology Median

Median of 656 stocks
MetricLTGOBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Latigo Biotherapeutics, Inc. (LTGO) carries a market capitalisation of $1.53B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 59.

Over the past 52 weeks the price has ranged from $17.22 to $25.93. LTGO last closed at $23.04 on September 4, 2026. That is +$0.56 (+2.49%) against the previous close. The latest close sits 33.8% above that 52-week low.

Financial Health

In fiscal 2025, Latigo Biotherapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $109.17M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −1.89.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Growth & Income

The record shows no dividend for LTGO.

2026 is still running; the price is +26.25% year to date.

Peer Comparison

Latigo Biotherapeutics, Inc. (LTGO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Latigo Biotherapeutics, Inc. LTGO $1.53B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Latigo Biotherapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Latigo Biotherapeutics, Inc.

Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.

Visit website →